Skip to main content
. 2018 Mar 1;13(3):e0193171. doi: 10.1371/journal.pone.0193171

Table 1. Age related anti-EBV antibodies in all patients visiting the PUMC Hospital, Beijing, 2013–2017.

VCA IgG
Pos no. (%)
VCA IgM
Pos no. (%)
VCA IgA
Pos no. (%)
EA/D IgA
Pos no. (%)
EBNA1 IgG
Pos no. (%)
0–5y* 283(66.59) 65(14.57) 52(14.57) 26(7.12) 141(58.51)
6–10y 431(84.34) 55(10.24) 93(22.79) 39(9.18) 226(78.75)
11–20y 784(92.89) 123(10.41) 178(23.73) 95(12.20) 413(86.95)
21–30y 809(98.54) 88(6.25) 192(26.10) 120(15.33) 271(95.43)
31–40y 853(98.84) 40(3.06) 219(22.71) 123(11.80) 203(94.86)
41–50y 892(99.78) 36(2.76) 282(22.54) 171(13.13) 202(97.57)
51–60y 957(99.79) 37(2.62) 301(27.54) 184(15.79) 248(96.12)
61–101y 902(99.01) 29(2.03) 258(33.42) 146(18.36) 258(93.82)
Male 2905(94.23) 229(5.13) 864(25.62) 504(14.31) 938(86.93)
Female 3006(95.58) 244(5.35) 711(24.03) 400(12.76) 1024(87.90)
Total 5911(94.91) 473(5.24) 1575(24.87) 904(13.58) 1962(87.43)

* Actual numbers of patients in each (age) groups tested for each parameter could be calculated from the positive numbers divided by their percentages.